Indifferent Diagnosis- The Health of BioPharma in 2025

Length2h 35m

About this audiobook

Indifferent Diagnosis: The Health of BioPharma in 2025 is your inside pass to an industry running at two speeds—record-breaking M&A on one end, widespread cash-burn triage on the other. Veteran strategist Frank Dolan unpacks why 40 % of public biotechs are months from insolvency while giants like Pfizer and Novartis spend billions on de-risked assets; how AI, CRISPR, and next-gen delivery tech are redrawing drug-discovery maps; and where regulatory, demographic, and private-equity cross-currents will push the market next. Packed with hard data, boardroom stories, and survival playbooks, this audiobook arms executives, investors, and scientists with the context—and contrarian edge—needed to navigate 2025’s most volatile sector.

Artificial Intelligence

Futuristic

Genetic Engineering

Survival

Healing

Political Intrigue

Audiobook details

Rating★★★★★ 5.0 (3)

GenreBusiness and Economics

Length2 hrs 35 mins

Narrated bySelect Your Own

FormateBook with Audio

Publish dateJun 25, 2025

LanguageEnglish

1Introduction

12Chapter 11: Therapeutic Focus Areas in 2025

2Chapter 1: The State of Biopharma in 2025

13Chapter 12: The Role of Technology in Driving Innovation

3Chapter 2: M&A Activity: A Boon and a Burden

14Chapter 13: Regional Trends and Cross-Border Activities

4Chapter 3: Understanding Financial Distress in Biotech Companies

15Chapter 14: Understanding Risk Factors and Managing Market Volatility

5Chapter 4: The IPO Market: Is the Opportunity Shrinking?

16Chapter 15: The Future of Drug Development and Innovation

Show all chapters

6Chapter 5: Exploring Alternative Financing Strategies

17Chapter 16: The Impact of Demographic Changes on the Market

7Chapter 6: The Rise of Private Equity in the Biopharmaceutical Industry

18Chapter 17: Understanding the Competitive Landscape

8Chapter 7: Long-Term Growth Drivers: Key Factors Shaping Future Success

19Chapter 18: The Evolution of Business Models

9Chapter 8: Regulatory Challenges and Their Impact on the Industry

20Chapter 19: Lessons from 2025: Insights and Predictions for the Future

10Chapter 9: Investor Sentiment – Navigating Cautious Optimism

21Preparing for Future Market Changes

11Chapter 10: Building Strategic Partnerships and Collaborations

About the author

Frank F. Dolan

Over 25 years launching 15 medicines across 7 biopharmas, Frank F. Dolan mastered life science innovation. Transforming healthcare markets, introducing the GLP-1 class, and navigating billion dollar acquisitions required Frank to cast a vision of a future to compel others to believe, act, and execute. Currently he serves as founder and CEO of Arsenal Advisors, a media and intelligence firm serving biotech and pharma. His portfolio assets including MedicineToMarket.com and BioDataStudio reach 30k+ life-science executives each month influencing the decisions the shape the industry.View all by Frank F. Dolan